Table 3.

Outcome studies with different inhibition of platelet aggregation.

Study	Study patients	Clopidogrel dose	Platelet function assay	Platelet reactivity measure	End-point prediction
Matetzky et al. [123]	STEMI-PCI patients: 60	300 mg post-PCI	LTA (ADP-induced aggregation)	Patients stratified into 4 quartiles	MACE at 6 months   P < 0.01
Gurbel et al. [124]	ELECTIVE PCI, patients: 192	300/600 mg post PCI	LTA and TEG	Patients stratified in different quartiles	MACE at 6 months   P = 0.02
Bliden et al. [125]	ELECTIVE PCI, patients: 100	75 mg for >1 month	LTA and TEG	Preprocedural platelet aggregation in patients on clopidogrel	MACE at 12 months   P < 0.001
Bonello et al. [96]	ELECTIVE PCI, patients: 144	300 mg, 24 hours prior to PCI	VASP-P	PRI > 50%	MACE at 6 months   P < 0.01
Price et al. [73]	ELECTIVE PCI, patients: 380	600 mg, 12 hours prior to PCI	VerifyNow	PRU > 235	MACE at 6 months   P = 0.008
Marcucci et al. [74]	ACS-PCI patients: 683	600 mg prior to PCI	VerifyNow	PRU > 240	MACE at 12 months   CV death P = 0.034   MI P = 0.004
Migliorini et al. [126]	PCI-unprotected LM, patients: 215	600 mg prior to PCI	LTA	Platelet reactivity > 70%	MACE at 19.3 months   P = 0.005
El Ghannudi et al. [127]	ELECTIVE and URGENT PCI, patients: 461	300 or 600 mg	VASP-P	PRI > 61%	MACE at 9 months   P = 0.037
Breet et al. [79]	ELECTIVE PCI, patients: 1069	75 mg >5 days or 300 mg >24 hours prior or 600 mg >4 hours prior to PCI	LTA, VerifyNow, Plateletworks, IMPACT, Innovance PFA and PFA-100	Standard platelet function measurement values	MACE at 12 months

ADP: adenosine diphosphate; LM: left main; LTA: light transmittance aggregometry; CV: cardiovascular; MACE: major adverse cardiovascular events; MI: myocardial infarction; PFA: platelet function assay; PRI: platelet reactivity index; PRU: P2Y₁₂ reaction unit; TEG: thrombelastography; VASP-P: vasodilator-stimulated phosphoprotein phosphorylation. From [75].